

Press release 2010-12-16



A frame order of diode detectors to be delivered in 2010

C-RAD AB with its three fully owned subsidiaries is active in the field of radiation therapy. The subsidiary C-RAD Imaging is from January 2010 responsible for the manufacturing of the IBA diode detector program. IBA has placed a frame order of 4.3 MSEK for deliveries in 2010.

C-RAD Imaging is marketing a detector system based technology originally developed at CERN in Switzerland. The technology has been further developed by professor Brahme at the Karolinska Institutet in Stockholm for use in diagnostics and radiation therapy. The company will from 1 January 2010 be responsible for the development and manufacturing of the IBA diode detector program. The main application of diode detectors are in in-vivo dosimetry. Altogether 1400 diode detectors and diode detector systems will in 2010 be delivered to the IBA Dosimetry headquarter in Schwarzenbruck, Germany and for further deliveries to the world market. Deliveries will start in February. Due to change of product mix the value might vary.

These detectors will, as part of the IBA agreement, be sold by C-RAD in the Scandinavian countries, Norway excluded. The distribution agreement signed with IBA Dosimetry will bring synergies for C-RAD when selling direct to the radiation therapy clinics in Scandinavia. IBA is the world market leader in dosimetry for use in the medical field

Erik Hedlund, CEO, C-RAD AB:

"The relationship between IBA and C-RAD are for both parties long term and will bring synergies in the development, manufacturing and sales. Existing resources will more effectively be used. The representation of IBA Dosimetry in Scandinavia will add considerable business in direct sales."

For further information:

Erik Hedlund, CEO C-RAD AB, Telefon 018 - 66 69 31, E-post erik.hedlund@c-rad.se

About C-RAD AB

C-RAD develops new and innovative solutions for the use in advanced radiation therapy. The company group of C-RAD offers products and solutions for patient positioning, tumor localization and radiation treatment systems. End users are radiation therapy clinics worldwide. All product development is conducted in three fully owned subsidiaries; C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB. C-RAD Imaging AB is located in Östersund while the other companies are located in Uppsala. Numbers of employees are currently 19 people. The activity in C-RAD AB originates in research and development at the Karolinska Institutet in Solna and the The Royal Institute of Technology in Stockholm. Sales of the company's first product, the Sentinel system' started in autumn 2006. Co-operation agreements have been signed with the radiation therapy company Elekta and the

Belgian company IBA. On major markets in Europe, North America and East Asia the company is represented by distributors normally specialized in radiation therapy.

C-RAD is since July 2007 listed at Aktietorget. From 8 March 2010 C-RAD will be traded at OMX First North Premier.